Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective faithfully but unsuccessfully to produce a single therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be being used is an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV have been closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the last few shares of mine. The first CytoDyn article of mine, “CytoDyn: What To Do When It is Too Good In order to Be True?”, set out what follows prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely promotional image in the Uptick Newswire interview which I came away with a bad impression of the business.

Irony of irony, my bad impression of the company has grown steadily, yet the disappointment hasn’t been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger yet still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much-storied treatment (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this know-how and also connected intellectual property from Progenics to CytoDyn, and also approximately twenty five million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 zillion) and also the first brand new drug program approval ($five million), as well as royalty payments of 5 percent of net sales upon commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many indications and numerous therapies, it has this single treatments and a “broad pipeline of indications” because it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely advantageous therapy in dozens of indications.

The opening banner of its on its site (below) shows an energetic organization with diverse interests albeit centered on leronlimab, multiple disease types, multiple publications and multiple presentations.

Can all this be smoke cigarettes and mirrors? That is a question I’ve been asking myself with the very beginning of the interest of mine in this particular business. Judging with the multiples of a huge number of diverse comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am far from alone in this particular question.

CytoDyn is a classic battleground, or even some might say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *